Evidence map›Paper›PMID 32468498›Full record

ArticleInflammation2020

1,7-Dihydroxy-3,4-Dimethoxyxanthone Inhibits Lipopolysaccharide-Induced Inflammation in RAW264.7 Macrophages by Suppressing TLR4/NF-κB Signaling Cascades.

Meng-Qing Tao, Cong-Lan Ji, Yi-Jin Wu, Ji-Yang Dong, Yan Li, Opeyemi Joshua Olatunji, Jian Zuo

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Formosanin C attenuates lipopolysaccharide-induced inflammation through nuclear factor-κB inhibition in macrophages.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2021
    Article
  8. Journal of inflammation research · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Meng-Qing Tao *Yijishan Hospital of Wannan Medical College, Wuhu, 241000, China.
Cong-Lan Ji *School of Pharmacy, Anhui College of Traditional Chinese Medicine, Wuhu, 241000, China.
Yi-Jin WuThe Second Affiliated Hospital of Wannan Medical College, Wuhu, 241000, Anhui, China.
Ji-Yang DongDepartment of Electronic Science, Xiamen University, Xiamen, 361005, China.
Yan LiYijishan Hospital of Wannan Medical College, Wuhu, 241000, China.
Opeyemi Joshua OlatunjiFaculty of Traditional Thai Medicine, Prince of Songkla University, Hat Yai, 90110, Thailand.
Jian ZuoYijishan Hospital of Wannan Medical College, Wuhu, 241000, China. zuojian8178@163.com.ORCID https://orcid.org/0000-0003-4940-9408
Wannan Medical College · CNAnhui University of Traditional Chinese Medicine · CNPrince of Songkla University · THXiamen University · CN

Funding

National Natural Science Foundation of China 81603388 and 81973823Talent Cultivation and International Academic Visiting Project for College Scholar of Anhui Province gxfxZD2016163
6 · The paper itself

Abstract

Securidaca inappendiculata Hassk. is a traditional Chinese anti-rheumatic herbal medicine native to southern China. In this study, we identified a possible TLR4 inhibitor from this plant. General effects of its xanthone-rich fraction (XRF) on inflammation in vitro were investigated by immunoblotting experiments performed on lipopolysaccharides (LPS)-treated RAW264.7 cells, and the possible ligand of TLR4 within was screened out by analyzing chemical composition differences of the XRF containing cell culture medium under different inflammatory circumstances. The interaction between ligand and TLR4 was validated by cellular thermal shift assay (CETSA) and molecular docking simulation, and TLR4/NF-κB pathway status was investigated by immunoprecipitation, ELISA, immunofluorescence, dual-luciferase reporter, and immunoblotting experiments. Treatment with XRF resulted in significant decrease in p-p65 and p-JNK, and the signal accounting for 1,7-dihydroxy-3,4-dimethoxyxanthone (XAN) at 12.5 min with mass of 289.29 was greatly decreased in XRF containing medium after LPS stimulus because of enhanced interaction with increased TLR4. CETSA and molecular docking simulation demonstrated that XAN could bind to TLR4 directly on a smooth region adjacent to its contact interface with MD-2. XAN treatment inhibited the dimerization of TLR4 and transcriptional activity of NF-κB in HEK293T cells and decreased p65 accumulation in nucleus and pro-inflammatory cytokines production in RAW264.7 cells receiving LPS treatment. Overall evidences suggest that XAN could be a selective TLR4 inhibitor with potent anti-inflammatory effects. Also, it indicated that xanthone derivatives could have promising clinical application in many immune-mediated inflammations by acting as TLR4 inhibitors.

Indexed as

AnimalsAnti-Inflammatory AgentsDose-Response Relationship, DrugDrugs, Chinese HerbalHEK293 CellsHumansInflammationLipopolysaccharidesMacrophagesMiceNF-kappa BProtein Structure, TertiaryRAW 264.7 CellsToll-Like Receptor 4XanthonesAnti-Inflammatory AgentsDrugs, Chinese HerbalLipopolysaccharidesNF-kappa BTlr4 protein, mouseToll-Like Receptor 4veratrilogeninXanthonesanti-inflammationmolecular dockingNF-κBrheumatoid arthritisUPLC-MS/MS

Identifiers

PMID32468498
OpenAlexW3030583622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.